10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2019

OR

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______________

Commission File Number: 1-9927

ADVANZEON SOLUTIONS, INC.

(Exact name of registrant as specified in its charter)

Delaware	95-2594724
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

2901 W. Busch Blvd. Suite 701 Tampa, FL	33618
(Address of principal executive offices)	(Zip Code)

813-517-8484

(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such fling requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.

1

Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer ☐	Smaller reporting company ☒
	Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of November 13, 2019, the Registrant had outstanding 71,661,656 shares of its $0.01 par value Common Stock.

2

ADVANZEON SOLUTIONS, INC.

TABLE OF CONTENTS

		Pages
PART I.	Financial Information
Item 1.	Consolidated Financial Statements
	Consolidated Balance Sheets as of September 30, 2019 (unaudited) and December 31, 2018	4 - 5
	Consolidated Statements of Operations for the Three and Nine Month Periods Ended September 30, 2019 and 2018 (unaudited)	6
	Consolidated Statement of Stockholders' Deficiency For the Nine Month Period Ended September 30, 2019 (unaudited) and December 31, 2018	7
	Consolidated Statements of Cash Flows for the Nine Month Periods Ended September 30, 2019 and 2018 (unaudited)	8
	Notes to Consolidated Financial Statements	9 - 17
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	18 - 26
Item 3.	Quantitative and Qualitative Disclosure about Market Risk	27
Item 4.	Controls and Procedures	27 - 28
PART II.	Other Information
Item 1.	Legal Proceedings	29
Item 1A.	Risk Factors	29
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	29 - 42
Item 3.	Exhibits	42

3

ADVANZEON SOLUTIONS, INC.

PART I – FINANCIAL INFORMATION

CONSOLIDATED BALANCE SHEETS

September 30, 2019 (unaudited) and December 31, 2018

ASSETS
	September 30, 2019		December 31,
	(unaudited)		2018
CURRENT ASSETS
Cash	$	64,057	$	25,036
Accounts receivable		25,171		24,890
Current portion of right of use asset		124,311		53,634
Other current assets		2,354,854		828,996
Total current assets		2,568,393		932,556
PROPERTY, PLANT, AND EQUIPMENT
Property and equipment, net		1,324		—
Leasehold improvements, net		—		299
Total property, plant, and equipment		1,324		299
RIGHT OF USE ASSET, NET OF CURRENT PORTION		171,885		28,920
TOTAL ASSETS	$	2,741,602	$	961,775

The accompanying notes are an integral part of these consolidated financial statements.

4

ADVANZEON SOLUTIONS, INC.

PART I – FINANCIAL INFORMATION

CONSOLIDATED BALANCE SHEETS

September 30, 2019 (unaudited) and December 31, 2018

LIABILITIES AND STOCKHOLDERS' DEFICIENCY
		September 30, 2019			December 31,
		(unaudited)			2018
CURRENT LIABILITIES
Related party loans payable	$	444,920		$	737,023
Account payable		1,423,284			700,067
Debt		12,163,189			10,087,939
Contingent liability		642,659			642,659
Current portion of lease liability		124,311			53,634
Other accrued expenses		15,734,145			14,614,772
Total current liabilities		30,532,508			26,836,094
LEASE LIABILITY, NET OF CURRENT PORTION		171,885			28,920
TOTAL LIABILITIES		30,704,393			26,865,014
STOCKHOLDERS' DEFICIENCY
Preferred stock, $.001 par value; 1,000,000
shares authorized, as of September 30, 2019
and December 31, 2018		—			—
Series C Convertible Preferred; $.001 par value;
14,400 shares authorized; 10,434 shares
issued and outstanding as of September 30, 2019
and December 31, 2018		10			10
Series D Convertible Preferred; $.001 par value;
7,000 shares authorized; 250 shares issued
and outstanding as of September 30, 2019
and December 31, 2018		—			—
Remaining Preferred stock; $.001 par value;
978,600 shares as of September 30, 2019
and December 31, 2018		—			—
Common stock, $0.01 par value; 1,000,000,000
shares authorized; 67,361,656 and 66,661,656
shares issued and outstanding as of
Septmeber 30, 2019 and December 31, 2018		673,617			666,617
Additional paid in capital		28,036,007			28,012,007
Accumulated deficit		(56,672,425	)		(54,581,873	)
Total stockholders' deficiency		(27,962,791	)		(25,903,239	)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIENCY	$	2,741,602		$	961,775

The accompanying notes are an integral part of these consolidated financial statements.

5

ADVANZEON SOLUTIONS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

For the Three and Nine Month Periods Ended September 30, 2019 and 2018 (unaudited)

	Three-Month Period Ended						Nine-Months Period Ended
	September 30,						September 30,
	2019			2018			2019			2018
Revenues:
Obstructive sleep apnea (OSA)	$	68,173		$	99,083		$	226,549			449,650
Total revenues		68,173			99,083			226,549			449,650
Costs and expenses:
Costs of revenues		2,394			46,028			110,211			280,372
General and administrative		428,077			409,419			1,269,920			1,396,478
Depreciation and amortization		84			149			524			449
Total costs and expenses		430,555			455,596			1,380,655			1,677,299
Loss from operations		(362,382	)		(356,513	)		(1,154,106	)		(1,227,649	)
Other income (expense):
Interest expense		(383,798	)		(307,922	)		(1,052,991	)		(1,148,795	)
Interest income		29			—			6,023			—
Legal settlement		—			—			112,172			328,269
State tax penalty		(1,650	)		—			(1,650	)		—
Extinguishment of loan due to shareholder		—			—			—			7,771,140
Settlement of prior accounting services		—			—			—			(240,000	)
Other income		—			—			—			2,380
Total other income (expense)		(385,419	)		(307,922	)		(936,446	)		6,712,994
Income taxes		—			—			—			—
Net (loss) income	$	(747,801	)	$	(664,435	)	$	(2,090,552	)	$	5,485,345
PER SHARE INFORMATION
Net (Loss) Income Per Common Share	$	(0.01	)	$	(0.01	)	$	(0.03	)	$	0.08
Weighted Average Number of Common
Shares Outstanding		67,361,656			66,661,656			67,140,411			65,849,175

The accompanying notes are an integral part of these consolidated financial statements.

6

ADVANZEON SOLUTIONS, INC.

CONSOLIDATED STATEMENT OF STOCKHOLDERS’ DEFICIENCY

For the Nine Month Period Ended September 30, 2019 (unaudited) and December 31, 2018

	Series C		Series C
	Convertible		Convertible		Common
	Preferred		Preferred		Stock		Common		Additional
	Stock Number		Stock		Stock Number		Stock		Paid-in		Accumulated
	of Shares		Amount		of Shares		Amount		Capital		Deficit			Total
Balance at December 31, 2018		10,434	$	10		66,661,656	$	666,617	$	28,012,007	$	(54,581,873	)	$	(25,903,239	)
Stock issued for services		—		—		200,000		2,000		14,000		—			16,000
Sale of stock		—		—		500,000		5,000		10,000		—			15,000
Net loss		—		—		—		—		—		(2,090,552	)		(2,090,552	)
Balance at September 30, 2019		10,434	$	10		67,361,656	$	673,617	$	28,036,007	$	(56,672,425	)	$	(27,962,791	)

The accompanying notes are an integral part of these consolidated financial statements.

7

ADVANZEON SOLUTIONS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

For the Nine Month Periods Ended September 30, 2019 and 2018 (unaudited)

	Nine Month Periods Ended
	September 30,
	2019			2018
CASH FLOWS FROM OPERATING ACTIVITIES
Net (loss) income	$	(2,090,552	)	$	5,485,345
Adjustments to reconcile net (loss) income to net cash used in operating activities:
Depreciation and amortization		524			449
Stock issued for services		16,000			240,000
Extinguishment of loan due to shareholder
and accrued interest		—			(7,771,140	)
Amortization of right of use assets		62,135			—
Net changes in assets and liabilities:
Accounts receivable		(281	)		(34,493	)
Other current assets		(1,525,858	)		(700,842	)
Payments on lease liabilities		(62,135	)		—
Accounts payable		431,114			520,379
Contingent liability		—			152,664
Accrued interest - related party		—			(246,568	)
Other accrued expenses		1,119,373			1,328,842
Net cash used in operating activities		(2,049,680	)		(1,025,364	)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property, plant, and equipment		(1,549	)		—
Net cash used in investing activities		(1,549	)		—
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from promissory notes		2,100,250			1,079,223
Payments on debt		(25,000	)		—
Sale of stock		15,000			—
Net cash provided by financing activities		2,090,250			1,079,223
Net increase in cash		39,021			53,859
CASH - Beginning of Year		25,036			18,200
CASH - END OF PERIOD	$	64,057		$	72,059
Supplemental disclosures of cash flow information:
Cash paid during the period for:
Interest	$	6,960		$	—
Income taxes	$	—		$	—
Recording of right of use assets under
lease agreements (ASU 2016-02)	$	390,260		$	—
Schedule of non-cash investing transactions:
Convertible promissory note converted to common stock	$	—		$	51,231

The accompanying notes are an integral part of these consolidated financial statements.

8

ADVANZEON SOLUTIONS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1. DESCRIPTION OF THE COMPANY’S BUSINESS AND BASIS OF PRESENTATION

The consolidated financial statements include the accounts of Advanzeon Solutions, Inc and its wholly owned subsidiary, and its respective subsidiaries (collectively referred to herein as, the “Company,” “Advanzeon,” “we”, “us,” or “our”).

In the opinion of management, the accompanying unaudited financial statements contain all adjustments necessary to present fairly the Company's financial position as of December 31, 2018, the changes therein for the three and nine month periods then ended and the results of operations for the three and nine month periods ended September 30, 2019 and 2018.

The financial statements included in the Form 10-Q are presented in accordance with the requirements of the Form and do not include all of the disclosures required by accounting principles general accepted in the United States of America. For additional information, reference is made to the Company's annual report on Form 10-K for the fiscal year ended December 31, 2018, filed May 24, 2019. The results of operations for the three and nine month periods ended September 30, 2019 and 2018, are not necessarily indicative of operating results for the full year.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Established in 1969, Advanzeon Solutions, Inc., (formerly Comprehensive Care Corp.) (“Advanzeon”, “we”, “Parent”, or the “Company”), through its wholly-owned subsidiary Pharmacy Value Management Solutions, Inc.,(“PVMS”) and its wholly-owned subsidiaries during 2015, and partly in 2016, provided managed care services by acting as the administrator for certain administrative service agreements in the behavioral health and substance abuse fields. We primarily offered these services to commercial, Medicare, Medicaid, Children’s Health Insurance Program (“CHIP”) health plans, as well as self-insured companies. Our managed care operations consisted solely of servicing administrative service agreements. Starting in July of 2015, we implemented our comprehensive sleep apnea program, called “SleepMaster Solutions” ™. SleepMaster Solutions (“SMS”) utilizes an administrative system for the convenient identification/testing and therapy of Obstructive Sleep Apnea (“OSA”). We partnered with a national health care provider by initiating a sleep apnea wellness program whereby we screened, tested and when needed, offered treatment programs for treating this disorder. We also contracted with a union to treat its driver members. Beginning in 2017, our only business was our SMS sleep apnea program.

The Company has elected to not adopt the option available under United States generally accepted accounting principles (“GAAP”) to measure any eligible financial instruments or other items at fair market value at this time. Accordingly, the Company measures all of its assets and liabilities on the historical cost basis of accounting, except as otherwise required by GAAP.

Inter-company accounts and transactions have been eliminated in consolidation. Certain minor reclassifications of prior period amounts have been made to conform to the current period presentation.

Use of Estimates - The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts. Actual results could differ from these estimates. Estimates involved in the determination of an allowance for doubtful accounts receivable are considered by management as particularly susceptible to material change in the next year. Other significant estimates relate to stock-based compensation, warrants and beneficial conversion features.

9

ADVANZEON SOLUTIONS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Accounts Receivable - Accounts receivable is carried at its estimated collectible value. Since customer credit is generally extended on a short-term basis, accounts receivable does not bear interest and are uncollateralized. We manage credit risk and determine necessary allowances by evaluating customers’ credit worthiness before extending credit and periodically for collectability, based primarily on customers’ past credit history and current financial conditions and general economic conditions, results of prior collection efforts, the relative strength of our relationship therewith and, in the event of a dispute, its legal position and the estimated cost of proposed collection proceedings. Management has not established a policy for when to charge off uncollectible accounts receivable or to use external collection agencies and makes such decisions on a case-by-case basis. The maximum losses that the Company would incur if a customer failed to pay would be limited to the carrying value of the receivable.

Revenue Recognition- The Company is on an accrual basis and revenue is recognized when billed, which is approximately when the testing service is performed or CPAP machine is shipped.

Property and Equipment - Property and equipment, as described in Note 4, is stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives ranging from 2 to 12 years.

Leasehold Improvement - Leasehold improvement, as described in Note 5, is stated at cost less accumulated amortization. Leasehold improvements are amortized over the shorter of the lease term or the asset’s useful life.

Fair Value Measurements - The carrying amounts of cash, accounts receivable and accounts payable approximate their estimated fair value due to the short-term nature of these instruments. Since our other financial liabilities are not traded in an open market, we generally use a present value technique, which is a level 3 input, as defined in GAAP, to measure the estimated fair value of these financial instruments, except for valuing stock options and warrants (see below). The rate used for discounting expected cash flows is a risk-free rate adjusted for systematic and unsystematic risk.

The carrying amounts of long-term debt and estimated fair values of the attached warrants at September 30, 2019 and December 31, 2018 are as follows:

	September 30, 2019				December 31, 2018
			Estimated				Estimated
			Fair Value of				Fair Value of
	Carrying		Attached		Carrying		Attached
	Amount		Warrants		Amount		Warrants
Convertible promissory notes	$	7,375,173	$	—	$	5,299,923	$	—
Short term notes payable	$	4,788,016	$	—	$	4,788,016	$	—
Loan payable related party		444,920		—		737,023		—
	$	12,608,109	$	—	$	10,824,962	$	—

During the nine month period ended September 30, 2019, there have been 47 additional convertible notes issued totaling $2,100,250 and one note paid off totaling $25,000.

10

ADVANZEON SOLUTIONS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Cost of Revenues- Costs of services consist of supplies and operating expenses. Supplies are recognized in the period in which a patient actually receives the supplies.

Right of Use Assets and Lease Liabilities - During the quarter ended March 31, 2019, the Company implemented Accounting Standards Update 2016-02, Leases. Under the new guidance, a lessee must record a liability for lease payments (referred to as the lease liability) and an asset for the right to use the leased asset during the lease term (referred to at the right of use asset) for all leases, regardless of whether they are designated as finance or operating leases. This election requires the lessee to recognize lease expense on a straight-line basis over the lease term. The right of use assets and corresponding right of use liabilities have been recorded using the present value of the leases. See Notes 10 and 11 within the financial statement for additional disclosure on leases.

Income Taxes - We are subject to the income tax jurisdictions of the U.S. and multiple state tax jurisdictions. However, our provisions for income taxes for 2018 and 2019 include only state income taxes.

Management has evaluated our tax positions taken or to be taken on income tax returns that remain subject to examination (i.e., tax years 2016 and thereafter federally), and has concluded that there have been no uncertain tax positions (as defined in GAAP) taken that require recognition or disclosure in the consolidated financial statements. In the event of any income tax-related interest or penalties are incurred, they would be included in general and administrative expense.

Stock Options and Warrants - We grant stock options and warrants to our employees, non-employee directors, note holders and certain consultants allowing them to purchase our common stock pursuant to approved terms. The estimated value of the warrants issued with debt instruments is recorded as a discount on notes payable and amortized as interest expense over the term of the notes using the effective interest method.

3. OTHER CURRENT ASSETS

 
Other current assets consists of the following at September 30, 2019 and December 31, 2018:

	September 30, 2019		December 31, 2018
Due from escrow account	$	1,918,898	$	472,788
Loans to others		22,459		—
Security deposit		5,500		13,500
Capitalized portion of lease		2,094		2,951
Prepaid expenses		71,394		5,248
Miscellaneous receivable		334,509		334,509
Other current asset	$	2,354,854	$	828,996

11

ADVANZEON SOLUTIONS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

4. PROPERTY AND EQUIPMENT

Property and equipment, net, consists of the following at September 30, 2019 and December 31, 2018:

	September 30, 2019			December 31, 2018
Property and equipment	$	1,549		$	—
Less accumulated depreciation		(225	)		—
Property and equipment - net	$	1,324		$	—

Depreciation expense for the nine month periods ended September 30, 2019 and 2018 is $225 and $0, respectively. A computer was acquired in February of 2019.

5. LEASEHOLD IMPROVEMENT

Leasehold improvement, net, consists of the following at September 30, 2019 and December 31, 2018:

	September 30, 2019			December 31, 2018
Leasehold improvements	$	2,992		$	2,992
Less accumulated amortization		(2,992	)		(2,693	)
Leasehold improvements - net	$	—		$	299

Amortization expense for the nine month periods ended September 30, 2019 and 2018 is $299 and $449, respectively.

6. RELATED PARTY LOANS PAYABLE

The Company has received financing from Management of the Company as well as from members of our Board of Directors. These individuals are deemed to be related parties to the Company and their indebtedness must be disclosed separately.

As of September 30, 2019 and December 31, 2018, there are the following related party notes payable:

	September 30, 2019		December 31, 2018
Related party loans payable	$	444,920	$	737,023

12

ADVANZEON SOLUTIONS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

7. DEBT

As of September 30, 2019 and December 31, 2018, the balance was as follows:

	September 30, 2019		December 31, 2018
Notes payable	$	12,163,189	$	10,087,939

During the nine month period ended September 30, 2019, there have been 47 additional convertible-promissory notes totaling $2,100,250. One $25,000 convertible promissory note was repaid with interest of $6,960 during the third quarter 2019. One previous $50,000 convertible-promissory note was converted into stock during the year ended December 31, 2018.

Break-out of debt between the parent company and our subsidiary PVMS is as follows:

	September 30, 2019		December 31, 2018
Advanzeon parent	$	5,010,016	$	5,010,016
PVMS		7,153,173		5,077,923
	$	12,163,189	$	10,087,939

At PVMS, the total of notes issued year-to-date and their dollar values were as follows:

	September 30, 2019		December 31, 2018
Number of notes issued		47		31
Dollar value	$	2,100,250	$	1,751,923

All debt are short-term in nature, one-year maturity date. All debt issued has a stated interest rate of 12% per year.

8. CONTINGENT LIABILITY

Contingent liability consisted of 3 items:

1. a lawsuit against the Company for $450,000 from the son of a deceased promissory note holder. This matter has been dismissed twice by the judge but is ongoing due to appeals. This case should expire in June or July for lack of prosecution.

2. interest payable in the amount of $171,247 to the same person listed in (1). This interest is related to the lawsuit reference in (1).

3. Advanzeon won a decision on a court case against Universal Healthcare. The attorney's fees relating to this matter total $21,412. This fee will be paid out of the proceeds of the case when collected.

13

ADVANZEON SOLUTIONS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

As of September 30, 2019 and December 31, 2018, the balance of this indebtedness is as follows:

	September 30, 2019		December 31, 2018
Disputed note payable	$	450,000	$	450,000
Disputed interest payable		171,247		171,247
Pending attorney fees		21,412		21,412
Total contingent liability	$	642,659	$	642,659

9. OTHER ACCRUED LIABILITIES

As of September 30, 2019 and December 31, 2018, the balance of other accrued liabilities is as follows:

	September 30, 2019		December 31, 2018
Management compensation	$	8,873,802	$	8,873,802
Accrued interest non-related party		5,839,509		4,809,644
Board of Director fees		1,012,500		900,000
State fees		—		21,000
Payroll liabilities		3,725		2,927
Accrued wages and related		4,609		7,399
Total other accrued debt	$	15,734,145	$	14,614,772

10. RIGHT OF USE ASSETS

The Company entered into two leases for office space and one automobile lease prior to the end of the quarter ended September 30, 2019 that are classified as right of use assets and lease liabilities. The lease for the Company’s office spaces expire in April 2020 and June 2022. The lease for the automobile expires in June 2021. As the implicit interest rate is not readily identifiable in the leases, the Company calculated the present a value of the leases using the average commercial real estate interest rate of 5.50% at the commencement of the office leases and the interest of 2.99% for the automobile lease. Applying the commercial rate, the Company calculated the present value of $361,223 for the office leases and $29,037 for the automobile leasing, that are being amortized over the life of the leases.

14

ADVANZEON SOLUTIONS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

As of September 30, 2019, the right of use assets associated with future operating leases are as follows:

Total present value of right of use assets
under lease agreements	$	390,260
Amortization of right of use assets		(94,064	)
Total right of use assets as of September 30, 2019	$	296,196

Total amortization expense related to the right of use assets under the lease agreements was $62,135 and $0 for the nine month periods ended September 30, 2019 and 2018, respectively.

11. RIGHT OF USE LEASE LIABILITIES

As disclosed in Note 10, the Company entered into two leases for office space and automobile lease prior to the quarter ended September 30, 2019 that are classified as right of use assets and lease liabilities.

As of September 30, 2019, the lease liabilities associated with future payments due under the leases are as follows:

Total present value of future lease payments	$	390,260
Principal payments made as of the quarter
ended September 30, 2019		(94,064	)
Total right of use lease liabilities as of September 30, 2019	$	296,196

The following is a schedule of future minimum lease payments under the right of use lease agreements together with the present value of the net minimum lease payments as of September 30, 2019:

Total future minimum lease payments	$	317,251
Less present value discount		21,055
Total right of use lease liabilities as of September 30, 2019		296,196
Less current portion due within one year		124,311
Long-term right of use liabilities	$	171,885

15

ADVANZEON SOLUTIONS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Total maturities of lease liabilities as of September 30, 2019 are as follows:

	Total future
	minimum lease		Present value		Right of use
	payments		discount		lease liabilities
2020	$	136,858	$	12,547	$	124,311
2021	$	106,330	$	6,839	$	99,491
2022		74,063		1,669		72,394
	$	317,251	$	21,055	$	296,196

12. COMMON STOCK

During the nine month period ended September 30, 2019, the Company issued 700,000 shares of its common stock as follows:

On March 21, 2019, the Company issued 200,000 shares of its common stock to its Securities Exchange Commission counsel, who elected to take common stock in the Company as partial payment of its legal fees. The total value shares were valued at $0.08 per share on the total value of $16,000.

Additionally, on March 29, 2019, the Company issued 500,000 shares of its common stock to an existing shareholder and warrant holder, who elected to exercise his warrants to purchase 500,000 shares of the Company's common stock for $15,000. The warrants were issued during May of 2017 for $0.03 per share.

During the nine month period ended September 30, 2018, the Company issued 2,000,000 shares of common stock for a legal settlement. The shares were issued at a value of $0.12 per share or for a total value of $240,000. In addition, the Company issued 1,597,971 shares for the conversion of a promissory note of $50,000 and accrued interest of $1,231. The stock was issued at a value of $0.03 per share. The Company relied on Section 4(a)(2) of the Securities Act of 1933, as amended, as the exemption from registration under the Act.

13. LEGAL PROCEEDINGS

The Company previously reported that the litigation between Rotech Healthcare, Inc. and Pharmacy Value Management Solutions, Inc. settled. The Company rejected the draft settlement terms and continues to aggressively defend this litigation.

Except as disclosed above and in Item 1, all of the legal proceedings for the nine-month period ended September 30, 2019, are disclosed in our annual report on Form10-K for the year ended December 31, 2018, filed on May 24, 2019.

16

ADVANZEON SOLUTIONS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

14. SUBSEQUENT EVENTS

In accordance with ASC Topic 855, “Subsequent Events”, the Company evaluated subsequent events through November 13, 2019, the date these financial statements were available to be issued. During its evaluation, the following subsequent events were identified:

Issuance of debt and warrants

Subsequent to the balance sheet date, the Company has issued $139,000 of convertible-promissory notes. All of the debt matures in 2020 and has a stated interest rate of 12% and is unsecured. Concurrent with the issuance of debt, the Company has issued 4,128,000 warrants at an average exercise price of $0.15 At the time of issuance, all warrants had a three or five year term.

Stock issued for services

 The Company issued 4,300,000 shares of restricted common stock to the investment banker, D. H. Blair Investment Banking Corp. The services were valued at $473,000 or $0.11 per share.

17

ADVANZEON SOLUTIONS, INC.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

General

The following information should be read in conjunction with the financial statements and notes thereto and in conjunction with Managements’ Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the fiscal year ended December 31, 2018.

This report includes forward-looking statements, the realization of which may be affected by certain important factors discussed previously above under Item 1A, “Risk Factors.”

Overview

The Company through its wholly owned subsidiary Pharmacy Value Management Solutions, Inc. administers and operates a medically driven sleep apnea program branded SleepMaster Solutions™ (“SMS”). Management believes that SMS is the largest provider of these combined services in the nation. We are in all 50 states and provide a turnkey solution designed to effectively keep drivers on the road with no down time, compliant with DOT regulations, improve their health, and significantly decrease legal liability risk for the employer. We are vertically integrated, and we provide a “Program” of services that addresses all the needs of a corporate transportation system, union or other driver-related organizations. We believe we are the only company capable of providing the full range of needed services in a timely manner.

Our services start with the identification of the target population and the potential risk the client currently has. We can do this through our SMS Program, which includes the ability to screen every driver to identify if signs and symptoms of sleep apnea are present. We can then take this data and provide the employer with a list of those drivers that should be tested and the statistical likelihood of the percentage of those drivers who will test positive for obstructive sleep apnea (OSA). Together with the employer/union, SMS provides a realistic time frame, actual total cost, and process for testing all drivers who need to be tested. For those drivers testing positive for OSA, we then provide the appropriate treatment such that the driver will meet the DOT requirements and remain on the road. We monitor 365 days per year driver’s usage of the treatment device according to DOT standards and we report that usage to all stakeholders as required/permitted. We utilize mathematical algorithms to determine if the driver is predicatively meeting the annual DOT requirements for usage. Using those predictive algorithms, we reach out to those drivers and provide case management, encouragement designed to solve problems such that the driver increases usage, if necessary, and remains compliant.

PVMS constructed its model based upon the foregoing principles. The SMS Program includes all processes attended in sleep apnea screening, testing, treatment, monitoring and overall management of commercial drivers’ as well as their employers’ needs. We have successfully established relationships with national health care clinic providers, all with certified medical examiner (“CME”) status. These clinics total almost 1,000 throughout the U.S. We also have both formal and informal relationships with employers; municipalities; a significant veteran’s group; union and non-union driving organizations; suppliers of home sleep testing equipment and a variety of OSA treatment devices; and, a national network of telemedicine sleep specialists covering all 50 states. We have an internal medical team for governance and protocol purposes and a customer service department that interfaces directly with our drivers. We also have a marketing team that regularly interfaces with our existing accounts and markets our services to potential new accounts. Our services are performed utilizing a best medical practices model and an efficient, cost-effective delivery system. We obtain the required equipment on a per order basis from a durable medical equipment distributor.

18

ADVANZEON SOLUTIONS, INC.

Revenue is recognized when billed, which is approximately when the testing service is performed, or CPAP machine is shipped.

During the nine-month period ending September 30, 2019, we continued to work with Concentra Health Services, Inc. toward the implementation of the program whereby the Company will serve as one of three of Concentra’s preferred national sleep apnea services providers. Concentra did not roll out this service until the middle of October. At the time of the roll out we were informed by Concentra that they anticipated the roll out would start slow and progressively build as their centers get used to the new process. As a result, our revenue for the period was not what we had expected. During the period the Company did see revenues coming from other third-party payor accounts that had been established in prior periods. These accounts include unions, municipalities, school districts and small to mid-size corporations-all authorizing the Company to bill them directly for providing our sleep apnea services to their members/employees. Subsequent to the period we announced the establishment of a relationship with All Aboard America, a part of All Aboard America Holdings, Inc., the fourth largest motor coach operator in North America. The Company will screen, test and treat all of its drivers and employees for sleep apnea via our SMS program. We expect to see an increase in our revenues during the fourth quarter as a result of our existing relationships and other potential accounts we are currently working to establish.

Three month periods ended September 30, 2019 and 2018

Sources of Revenue

A quantitative summary of our revenues by source category for the three month periods ended September 30, 2019 and 2018:

	2019		2018		Change
OSA- related	$	68,173	$	99,083	$	(30,910	)

Results of Operations

OSA services decreased to $68,173 in 2019 from $99,083 in 2018. The decrease was primarily the result of the timing of the Concentra launch. Earlier in the year, May 14, 2019, we reached an agreement with Concentra whereby Concentra engaged the Company, and the Company accepted the engagement, to serve as Concentra’s preferred national sleep apnea services provider. The launch by Concentra of this program, which included notifying all of the Concentra clinics of same, was delayed so that same launched much later than anticipated. Pending the launch, we were asked by Concentra, albeit informally, to cease activities in terms of having our regional representative’s visit the various Concentra clinics promoting our sleep apnea services to said clinics. We honored that request, and in so honoring the request, our sales were diminished. The launch occurred in mid-October and we were informed by Concentra that they anticipated the roll out would start slowly and progressively build as their centers get used to the new process. Nonetheless, as a result of the Concentra launch and the Pinnacle agreement, as described below, we expect to see an increase in revenue during the fourth quarter of 2019.

Cost of revenues decreased from $46,028 in 2018 to $2,394 in 2019 due to a decrease in sales and a settlement agreement from a previous supplier reducing the cost of sales by $34,400.

19

ADVANZEON SOLUTIONS, INC.

General and administrative expense

General and administrative expense in total for the three month periods ended September 30, 2019 and 2018 was as follows:

2019	$	428,077
2018		409,419
Change	$	18,658
Percentage Change		4.56	%

We evaluate expenses at the Parent company level as well as at our PVMS subsidiary. Expenses at the Parent company level include overhead and the cost of being a public entity. Expenses at PVMS are solely related to the OSA services segment. A breakdown of these expenses for the three month periods ended September 30, 2019 and 2018 is as follows:

	2019		2018		Change			Percent Change
Parent	$	118,096	$	130,218	$	(12,122	)		-9.31	%
PVMS		309,981		279,201		30,780			11.02	%
Total	$	428,077	$	409,419	$	18,658			4.56	%

Parent Company Level

	2019		2018		Change			Percent Change
Professional fees	$	34,329	$	49,735	$	(15,406	)		-30.98	%
Travel expense		—		1,500		(1,500	)		-100.00	%
Board of Directors fees		37,500		37,500		—			0.00	%
Rent expense		25,255		25,129		126			0.50	%
Other		21,012		16,354		4,658			28.48	%
Total G & A	$	118,096	$	130,218	$	(12,122	)		-9.31	%

 
Explanations of variations by line item follow:

Travel expense decreased by $1,500 due to main operations moving to the subsidiary level.

Professional fees decreased by $15,406. The decrease is a result of a $18,000 decrease in legal fees in the three month period ended September 30, 2019 compared to the three month period ended September 30, 2018.

Rent expense has stayed relatively the same.

Other general and administrative expense increased by $4,658. This increase was due to a new D&O Insurance expense of $16,000 while storage, travel, and marketing decreased by $9,000. Other miscellaneous items decreased by $2,300.

20

ADVANZEON SOLUTIONS, INC.

PVMS Subsidiary Level

	2019		2018		Change			Percent Change
Payroll related	$	129,457	$	141,516	$	(12,059	)		-8.52	%
Travel and related expense		60,048		61,003		(955	)		-1.57	%
Professional fees		53,454		21,550		31,904			148.05	%
Marketing costs		16,511		14,066		2,445			17.38	%
Automobile expense		6,733		5,015		1,718			34.26	%
Office supplies		13,191		13,481		(290	)		-2.15	%
Rent expense		12,941		7,400		5,541			74.88	%
Other		17,646		15,170		2,476			16.32	%
Total G & A	$	309,981	$	279,201	$	30,780			11.02	%

Explanations of variations by line item follow:

Payroll related expenses decreased $12,059. The Company no longer used 4 subcontractors in the three months ended September 30, 2019 that were used in the comparable period in 2018.

Travel expense stayed relatively the same.

Professional Fees increased $31,904. This increase is due to the new consulting services expense in the total of $31,500. In January 2019, we hired a law firm to begin litigation against our former accountants.

Marketing costs increased by $2,445 due to the increased visits to potential clinics in building up new clientele. In August 2019, we hired a new advertising firm.

Office supplies stayed relatively the same.

Rent expense increased by $5,541. The California office lease began mid-way through the three months period ended June 30, 2018. As of May 2019, the California office lease was renewed for a new monthly rate of $4,000. We pay the California lease payments on a residential unit that we use as an office for our account managers, sales and marketing staff. The unit is also used as a temporary residence for one of our national account managers while developing the West Coast market.

Other general and administrative expense stayed relatively the same.

Interest expense

Interest expense in total for the three month periods ended September 30, 2019 and 2018 was as follows:

2019	$	383,798
2018		307,922
Change	$	75,876
Percentage Change		24.64	%

21

ADVANZEON SOLUTIONS, INC.

A breakdown of the interest expense for the three month periods ended September 30, 2019 and 2018 is as follows:

	2019		2018		Change
Parent	$	172,720	$	163,092	$	9,628
PVMS		211,078		144,830		66,248
Total	$	383,798	$	307,922	$	75,876

Nine-month periods ended September 30, 2019 and 2018

Sources of Revenue

A quantitative summary of our revenues by source category for the nine month periods ended September 30, 2019 and 2018:

	2019		2018		Change
OSA- related	$	226,549	$	449,650	$	(223,101	)

Results of Operations

OSA services decreased to $226,549 in 2019 from $449,650 in 2018. The decrease was primarily the result of the timing of the Concentra launch. Earlier in the year, May 14, 2019, we reached an agreement with Concentra whereby Concentra engaged the Company, and the Company accepted the engagement, to serve as Concentra’s preferred national sleep apnea services provider. The launch by Concentra of this program, which included notifying all of the Concentra clinics of same, was delayed so that same launched much later than anticipated. Pending the launch, we were asked by Concentra, albeit informally, to cease activities in terms of having our regional representative’s visit the various Concentra clinics our sleep apnea services to said clinics. We honored that request, and in so honoring the request, our sales were diminished. The launch occurred in mid-October and we were informed by Concentra that they anticipated the roll out would start slowly and progressively build as their centers get used to the new process. Nonetheless, as a result of the Concentra launch and the Pinnacle agreement, as described below, we expect to see an increase in revenue during the fourth quarter of 2019.

Cost of revenues decreased to $110,211 in 2019 from $280,372 in 2018 due to a decrease in sales and a settlement agreement from a previous supplier reducing the cost of sales by $34,400.

General and administrative expense

General and administrative expense in total for the nine-month periods ended September 30, 2019 and 2018 was as follows:

2019	$	1,269,920
2018		1,396,478
Change	$	(126,558	)
Percentage Change		-9.06	%

22

ADVANZEON SOLUTIONS, INC.

We evaluate expenses at the Parent company level as well as at our PVMS subsidiary. Expenses at the Parent company level include overhead and the cost of being a public entity. Expenses at PVMS are solely related to the OSA services segment. A breakdown of these expenses as September 30, 2019 and 2018 is as follows:

								Percent
	2019		2018		Change			Change
Parent	$	470,917	$	484,377	$	(13,460	)		-2.78	%
PVMS		799,003		912,101		(113,098	)		-12.40	%
Total	$	1,269,920	$	1,396,478	$	(126,558	)		-9.06	%

Parent Company Level

								Percent
	2019		2018		Change			Change
Professional fees	$	245,594	$	213,766	$	31,828			14.89	%
Travel expense		3,815		25,367		(21,552	)		-84.96	%
Board of Directors fees		112,500		112,500		—			0.00	%
Office supplies		336		3,370		(3,034	)		-90.03	%
Rent expense		76,532		74,736		1,796			2.40	%
Other		32,140		54,638		(22,498	)		-41.18	%
Total general and administrative	$	470,917	$	484,377	$	(13,460	)		-2.78	%

Explanations of variations by line item follow:

Professional fees increased by $31,828. The increase is a result of a $53,000 increase in accounting fees, a $56,000 increase in audit fees, a $200 increase in other professional fees, and a $77,000 decrease in legal fees in the nine-month period ended September 30, 2019 compared to the nine-month period ended September 30, 2018.

Travel expense decreased by $21,552 due to main operations moving to the subsidiary level.

Rent expense remained relatively the same.

Other general and administrative expense decreased by $22,498.

Office supplies decreased by approximately $3,004 due to the operations moving to the subsidiary level.

Taxes decreased by approximately $17,000 due to a change in par value.

Advertising and promotion expense decreased by $8,000 due to marketing efforts moving to the subsidiary level.

23

 ADVANZEON SOLUTIONS, INC.

PVMS Subsidiary Level

								Percent
	2019		2018		Change			Change
Payroll related	$	341,769	$	408,172	$	(66,403	)		-16.27	%
Travel and related expense		151,372		200,446		(49,074	)		-24.48	%
Professional fees		135,201		83,206		51,995			62.49	%
Marketing costs		33,740		42,296		(8,556	)		-20.23	%
Dues and subscriptions		841		38,557		(37,716	)		-97.82	%
Office supplies		30,768		41,824		(11,056	)		-26.43	%
Rent expense		35,942		11,100		24,842			223.80	%
Other		69,370		86,500		(17,130	)		-19.80	%
Total general and administrative	$	799,003	$	912,101	$	(113,098	)		-12.40	%

Explanations of variations by line item follow:

Payroll related expenses decreased $66,403. The Company no longer used 3 subcontractors in the nine-month period ended September 30, 2019 that were used in the comparable period in 2018. There is an increase of $7,000 due to one of the employees receiving a raise in the nine-month period ended September 30, 2019.

Travel expense was $49,074 lower due to the sales force having cutback on traveling to trade shows and visiting existing and potential clinics. The sales force and supporting forces were most active in 2017 in building up new clientele while in 2018 expanding the services offered to current clientele from local to national.

Professional Fees increased $51,995. In January 2018, we hired an outside accountant for PVMS, whom we pay $7,000 per month. For the period January through March 2018 the fee was prorated to $11,000. There were also 2 consultants hired and paid $34,000 to improve social media and miscellaneous in the nine-month period ended September 30, 2018 that were not used in 2019. Legal expense increased by $23,000 due to litigation against our former accountants and former supplier.

Marketing costs decreased by $8,556 due to the sales force having cutback on traveling to trade shows and visiting existing and potential clinics. The sales force and supporting forces were most active in 2017 in building up new clientele while in 2018 expanding the services offered to current clientele from local to national.

Dues and Subscriptions comprised, in part, an annual payment to a national organization of $25,000 during the nine-month period of 2018 that is no longer used in the comparable period of 2019.

Office supplies decreased by $11,056 due to the expense of setting up the California location in 2018.

Rent expense increased $24,842 due to having a California office lease beginning in June of 2018.

Other general and administrative expense decreased by $17,130. This was mainly due to $11,500 in provider fees in 2018 that the Company is no longer using in 2019. In the nine months ended September 30, 2018, the Company had bad debt expense due to cleaning up it's receivables. During 2019, there has been very little bad debt.

24

ADVANZEON SOLUTIONS, INC.

Interest expense

Interest expense in total for the nine month periods ended September 30, 2019 and 2018 was as follows:

2019	$	1,052,991
2018		1,148,795
Change	$	(95,804	)
Percentage Change		-8.34	%

A breakdown of the interest expense for the nine month periods ended September 30, 2019 and 2018 is as follows:

	2019		2018		Change
Parent	$	498,905	$	780,936	$	(282,031	)
PVMS		554,086		367,859		186,227
Total	$	1,052,991	$	1,148,795	$	(95,804	)

25

ADVANZEON SOLUTIONS, INC.

Financial Condition

Liquidity and Capital Resources

During the nine month period ended September 30, 2019, we funded our operations from revenues and $2,100,250 in private borrowings. During the nine month period ended September 30, 2018, we funded our operations from revenues and $1,079,223 in private borrowings. We will continue to fund our operations from these sources until we are able to produce operating revenue sufficient to cover our cost structure. In the event we are not able to secure such funding, our operations will be adversely affected.

Short Term: We funded our operations with revenues from sales and private borrowings.

During the period in September 2019, we hired a person to serve as our national director of sales and marketing. On September 17, 2019, we entered into an agreement with D.H. Blair Investment Banking Corp. (“D.H. Blair”), whereby D.H. Blair will act as a financial and business advisor to the Company. Included in D.H. Blair’s undertaking is assisting the Company in conducting a series of transactions designed to position the Company to list its shares of common stock on The Nasdaq Stock Market. We will attempt to institute a series of corporate actions that will result in a recapitalization of our capital structure. Among the transactions being contemplated are attempting to reduce our stockholder deficiency by among other actions being able to convert a large portion of the accumulated debt to equity and raising more equity through the sale of our securities. As we are able to generate more revenue from operations, which we expect to do in the forthcoming periods, the deficiency should be reduced as well. Additionally, we may seek to institute a reverse common stock split. We can offer no assurances that any of these contemplated steps can be accomplished to the extent necessary to meet the eligibility requirements for listing.

Subsequent Events

In October, we announced that we had entered into an exclusive contract with Pinnacle National, a leading third party administrator serving union employees. Under the agreement, we will be positioned to screen, test and treat as needed, all Pinnacle National members electing to utilize this service at no cost to the members. All costs will be borne by Pinnacle National. This program will roll out in four segments, the first of which will impact in excess of 150,000 members. The number of members within each subsequent segment will increase. The term of the agreement is three years. We expect the first segment to begin immediately. On May 14, 2019, we entered into an agreement with Concentra Health Services, Inc., which agreement provided, in pertinent part, that Concentra engaged the Company, and the Company accepted such engagement, to serve as “ Concentra’s preferred national sleep apnea Services provider ” That program was launched by Concentra on October 16, 2019, pursuant to which Concentra notified all of its clinic facilities that the Company, along with two other providers have been designated as Concentra’s preferred providers with respect to sleep apnea services. At the time of the roll out we were informed by Concentra that they anticipated the roll out would start slowly and progressively build as their centers get used to the new process. We received an immediate response in that we started receiving referrals from Concentra clinics with which we had previously not received referrals. Although there can be no assurances, the Company would anticipate a substantial increase in its referrals from the Concentra clinics, nationwide. The Company also reached a verbal agreement with Sleep Cycle, a Swedish-based App company that markets an App that it has denominated as the “smart alarm clock.” Sleep Cycle’s App is reportedly the largest selling App, worldwide, with over 35 million downloads and in excess of 25 million active users. Through this App, Sleep Cycle collects significant data from its users such that it is probable that when analyzing the data, with the expertise we possess in the sleep apnea field, potential sufferers of sleep apnea can be readily identified. The Company’s agreement with Sleep Cycle is to initially test ours and Sleep Cycle’s theory of being able to identify sufferers of sleep apnea from Sleep Cycle’s existing data, and assuming the theory proves out, the Company and Sleep Cycle will jointly market our testing and treatment capabilities to select groups of Sleep Cycle’s App users. The initial market will be the United States. Existing plans call for the program to launch within the fourth quarter of 2019. Both Sleep Cycle and the Company are optimistic that the theory will prove out, thus providing the platform for the next marketing phase of this project.

Subsequent to the close of the period ended September 30, 2019 we issued a total of 4,128,000 common stock purchase warrants. we also issued 4,300,000 shares of our restricted common stock to our investment banker, D. H. Blair Investment Banking Corp., as consideration for advisory services and as provided in our Financial and Business Advisory Agreement dated September 17, 2019. The services were valued at $473,000. Additionally, we issued a total of $139,000 in convertible promissory notes.

26

ADVANZEON SOLUTIONS, INC.

Item 3. Quantitative and Qualitative Disclosures about Market Risk:

As a smaller reporting company, we are not required to make any disclosure.

Item 4. Controls and Procedures

Our management is responsible for establishing and maintaining adequate internal control over our financial reporting. Internal control over financial reporting is a process designed to provide reasonable assurance to our management and board of directors regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles.

Our internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect our transactions; (ii) provide reasonable assurance that transactions are recorded as necessary for preparation of our financial statements; (iii) provide reasonable assurance that receipts and expenditures of company assets are made in accordance with management authorization; and (iv) provide reasonable assurance that unauthorized acquisition, use or disposition of company assets that could have a material effect on our financial statements would be prevented or detected on a timely basis.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because changes in conditions may occur or the degree of compliance with the policies or procedures may deteriorate.

Our management assessed the effectiveness of our internal control over financial reporting as of September 30, 2019. This evaluation was based on criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission, or COSO, Internal Control-Integrated Framework. Based upon such assessment, our CFO concluded that, as of September 30, 2019, our internal controls over financial reporting were not optimally effective in the specific areas described in the paragraphs below.

As of September 30, 2019, our CFO identified the following specific material weaknesses in the Company’s internal controls over its financial reporting processes:

• Policies and Procedures for the Financial Close and Reporting Process – During the period of this report, the Company’s policies or procedures did not clearly define the roles in the financial reporting process. The various roles and responsibilities related to this process should be defined, documented, updated and communicated. Not having clear policies and procedures in place amounts to a material weakness in the Company’s internal controls over its financial reporting processes.

27

ADVANZEON SOLUTIONS, INC.

• Representative with Financial Expertise – For nine month period ended September 30, 2019, the Company did not continuously have an employee with the requisite knowledge and expertise to review the financial statements and disclosures at a sufficient level to monitor the financial statements and disclosures to the Company. Failure to have, continuously, an employee with such knowledge and expertise amounts to a material weakness to the Company’s internal controls over its financial reporting processes.

As a result of our retaining the services of an Outside Accountant in January 2018 and appointing an internal Company employee to interface with the Outside Accountant, we have instituted the following policies and procedures designed to address the material weaknesses cited above.

• All billing invoices prepared by the billing department are sent to the Outside Accountant for review and approval before sending out to the customer.

• Copies of all incoming payable invoices are sent to the Outside Accountant for review, approval and data entry into the accounting system. That way Corporate Office has the originals and the outside accountants have duplicate copies. Accounts Payable Aging Report is sent once a week from the Outside Accountants to the Corporate office. The Corporate office, along with Outside Accountants, decide on which bills to pay weekly. Electronic payments have a duel control approval system (one person is initiating the payment and another person is approving the payment). We also appointed the principle from our Outside Accountants to be our Chief Accounting Officer.

• Paperwork on all customer invoices, credit card payments and check payments received at Corporate are copied and forwarded to Outside Accountants. Customer invoices are recorded daily. Customer payments received are recorded daily. Customer payments are reconciled with the bank on a daily basis. Aged Accounts Receivable Reports are sent to Corporate by the Outside Accountants with suggestions on a regular basis.

• All bank accounts are reconciled monthly.

• Financial Statements are prepared and reviewed monthly.

 
The Company plans to further augment its addressing of material weaknesses, on an as-needed basis, by hiring additional accounting personnel once its initial corrective steps have been fully implemented, tested and found to be effective.

28

ADVANZEON SOLUTIONS, INC.

PART II-OTHER INFORMATION

Item 1. Legal Proceedings

With the exception of the matter set forth below, all of the legal proceedings for the nine-month period ended September 30, 2019, are disclosed in our annual report on Form 10-K for the year ended December 31, 2018, filed on May 24, 2019.

The Company previously reported that the litigation between Rotech Healthcare, Inc. and Pharmacy Value Management Solutions, Inc. settled. The Company rejected the draft settlement terms and continues to aggressively defend this litigation.

Item 1A. Risk Factors

The risk factors included in our Annual Report on Form 10-K for the year ended December 31, 2018 have not materially changed.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

With the exception of the matter set forth below, the sale of unregistered securities for the nine month period ended September 30, 2019 were disclosed in our annual report on Form 10-K for the year ended December 31, 2018, filed on May 24, 2019.

On May 1, 2019, we issued a convertible promissory note in the principle amount of $50,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 100,000 shares of the Company’s common stock at an exercise price of $0.15 per share.

On May 8, 2019, we issued a convertible promissory note in the principle amount of $50,250 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 105,000 shares of the Company’s common stock at an exercise price of $0.15 per share.

29

ADVANZEON SOLUTIONS, INC.

On May 21, 2019, we issued a convertible promissory note in the principle amount of $50,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 100,000 shares of the Company’s common stock at an exercise price of $0.15 per share.

On May 22, 2019, we issued a convertible promissory note in the principle amount of $50,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 100,000 shares of the Company’s common stock at an exercise price of $0.15 per share.

On May 22, 2019, we issued a convertible promissory note in the principle amount of $15,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 30,000 shares of the Company’s common stock at an exercise price of $0.15 per share.

30

ADVANZEON SOLUTIONS, INC.

On May 30, 2019, we issued a convertible promissory note in the principle amount of $50,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 100,000 shares of the Company’s common stock at an exercise price of $0.15 per share.

On May 31, 2019, we issued a convertible promissory note in the principle amount of $150,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 300,000 shares of the Company’s common stock at an exercise price of $0.15 per share.

On June 12, 2019, we issued a convertible promissory note in the principle amount of $100,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 200,000 shares of the Company’s common stock at an exercise price of $0.15 per share.

On June 19, 2019, we issued a convertible promissory note in the principle amount of $25,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 50,000 shares of the Company’s common stock at an exercise price of $0.15 per share.

31

ADVANZEON SOLUTIONS, INC. 

On June 24, 2019, we issued a convertible promissory note in the principle amount of $25,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 50,000 shares of the Company’s common stock at an exercise price of $0.15 per share.

On June 27, 2019, we issued a convertible promissory note in the principle amount of $25,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 50,000 shares of the Company’s common stock at an exercise price of $0.15 per share.

On July 1, 2019, we issued a convertible promissory note in the principle amount of $25,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 50,000 shares of the Company’s common stock at an exercise price of $0.15 per share.

32

ADVANZEON SOLUTIONS, INC.

On July 1, 2019, we issued a convertible promissory note in the principle amount of $25,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 50,000 shares of the Company’s common stock at an exercise price of $0.15 per share.

On July 1, 2019, we issued a convertible promissory note in the principle amount of $25,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 50,000 shares of the Company’s common stock at an exercise price of $0.15 per share.

On July 2, 2019, we issued a convertible promissory note in the principle amount of $25,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 50,000 shares of the Company’s common stock at an exercise price of $0.15 per share.

33

ADVANZEON SOLUTIONS, INC.

On July 2, 2019, we issued a convertible promissory note in the principle amount of $25,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 50,000 shares of the Company’s common stock at an exercise price of $0.15 per share.

On July 2, 2019, we issued a convertible promissory note in the principle amount of $25,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 50,000 shares of the Company’s common stock at an exercise price of $0.15 per share.

On July 2, 2019, we issued a convertible promissory note in the principle amount of $125,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 250,000 shares of the Company’s common stock at an exercise price of $0.15 per share.

On July 2, 2019, we issued a convertible promissory note in the principle amount of $25,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 50,000 shares of the Company’s common stock at an exercise price of $0.15 per share.

34

ADVANZEON SOLUTIONS, INC.

On July 3, 2019, we issued a convertible promissory note in the principle amount of $25,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 50,000 shares of the Company’s common stock at an exercise price of $0.15 per share.

On July 3, 2019, we issued a convertible promissory note in the principle amount of $100,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 200,000 shares of the Company’s common stock at an exercise price of $0.15 per share.

On July 5, 2019, we issued a convertible promissory note in the principle amount of $25,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 50,000 shares of the Company’s common stock at an exercise price of $0.15 per share.

35

ADVANZEON SOLUTIONS, INC.

On July 5, 2019, we issued a convertible promissory note in the principle amount of $50,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 100,000 shares of the Company’s common stock at an exercise price of $0.15 per share.

On July 8, 2019, we issued a convertible promissory note in the principle amount of $25,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 50,000 shares of the Company’s common stock at an exercise price of $0.15 per share.

On July 10, 2019, we issued a convertible promissory note in the principle amount of $50,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 100,000 shares of the Company’s common stock at an exercise price of $0.15 per share.

36

ADVANZEON SOLUTIONS, INC.

On July 10, 2019, we issued a convertible promissory note in the principle amount of $25,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 50,000 shares of the Company’s common stock at an exercise price of $0.15 per share.

On July 11, 2019, we issued a convertible promissory note in the principle amount of $30,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 60,000 shares of the Company’s common stock at an exercise price of $0.15 per share.

On July 11, 2019, we issued a convertible promissory note in the principle amount of $25,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 50,000 shares of the Company’s common stock at an exercise price of $0.15 per share.

On July 12, 2019, we issued a convertible promissory note in the principle amount of $25,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 50,000 shares of the Company’s common stock at an exercise price of $0.15 per share.

37

ADVANZEON SOLUTIONS, INC.

On July 17, 2019, we issued a convertible promissory note in the principle amount of $50,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 100,000 shares of the Company’s common stock at an exercise price of $0.15 per share.

On July 19, 2019, we issued a convertible promissory note in the principle amount of $50,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 100,000 shares of the Company’s common stock at an exercise price of $0.15 per share.

On August 24, 2019, we issued a convertible promissory note in the principle amount of $50,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 100,000 shares of the Company’s common stock at an exercise price of $0.15 per share.

38

ADVANZEON SOLUTIONS, INC.

On August 24, 2019, we issued a convertible promissory note in the principle amount of $200,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 400,000 shares of the Company’s common stock at an exercise price of $0.15 per share.

All of the convertible promissory notes listed above were issued to accredited investors, as that term is defined under the Section 501 of Regulation D, promulgated under the Securities Act of 1933, as amended. The warrants issued in connection with the promissory notes all have a cashless exercise feature.

On May 1, 2019, we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On May 1, 2019, we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On May 10, 2019, we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On May 11, 2019, we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On May 19, 2019, we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On May 22, 2019, we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On May 28, 2019, we issued 3,000,000 warrants to our Chief Accounting Officer. The warrants have a term of five years and an exercise price of $0.0650 per warrant.

39

ADVANZEON SOLUTIONS, INC.

On May 30, 2019, we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On May 31, 2019, we issued 638,888 warrants to our Chief Executive Officer in lieu of 2019 first quarter salary. The warrants have a term of five years and an exercise price of $0.09 per warrant.

On May 31, 2019, we issued 347,222 warrants to our President in lieu of 2019 first quarter salary. The warrants have a term of five years and an exercise price of $0.09 per warrant.

On June 03, 2019, we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On June 06, 2019, we issued 50,000 warrants to a member of our Dental Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On June 08, 2019, we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On June 08, 2019, we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On June 11, 2019, we issued 50,000 warrants to a member of our Dental Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On June 12, 2019, we issued 1,000,000 warrants to a member of our contracted supplier. The warrants have a term of five years and an exercise price of $0.11 per warrant.

On June 14, 2019, we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On June 20, 2019, we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On June 22, 2019, we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On June 24, 2019, we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

40

ADVANZEON SOLUTIONS, INC. 

On June 24, 2019, we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On June 25, 2019, we issued 718,750 warrants to our Chief Executive Officer in lieu of 2019 second quarter salary. The warrants have a term of five years and an exercise price of $0.08 per warrant.

On June 25, 2019, we issued 390,625 warrants to our consultant in lieu of 2019 second quarter salary. The warrants have a term of five years and an exercise price of $0.08 per warrant.

On June 27, 2019, we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On June 30, 2019, we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On June 30, 2019, we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On July 1, 2019, we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On July 1, 2019, we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On July 1, 2019, we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On July 1, 2019, we issued 50,000 warrants to a member of our Dental Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On July 6, 2019, we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On July 11, 2019, we issued 50,000 warrants to a member of our Dental Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On July 25, 2019, we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

41

ADVANZEON SOLUTIONS, INC.

On August 19, 2019, we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On August 31, 2019, we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On September 25, 2019, we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On September 30, 2019, we issued 136,905 warrants to our Chief Executive Officer in lieu of 2019 third quarter salary. The warrants have a term of five years and an exercise price of $0.42 per warrant.

On September 30, 2019, we issued 62,500 warrants to our consultant in lieu of 2019 third quarter salary. The warrants have a term of five years and an exercise price of $0.42 per warrant.

We relied on Section 4 (2) of the Securities Act of 1933, as amended and or Section 501 of Regulation D promulgated under said Act as the exemption from registration under the Act.

Item 3. Exhibits

Documents filed as part of this Report.

Exhibit 31.1 Certification of Clark A. Marcus pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

Exhibit 31.2 Certification of Arnold B. Finestone pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

Exhibit 32.1 Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Exhibit 32.2 Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

42

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Advanzeon Solutions, Inc.
	Registrant
Date: November 13, 2019	By:	/s/ Clark A. Marcus
		Clark A. Marcus, Chief Executive Officer

Date: November 13, 2019	By:	/s/ Arnold B. Finestone
		Arnold B. Finestone President and Chief Financial Officer

43

EX-31.1

EXHIBIT 31.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Clark A. Marcus, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Advanzeon Solutions, Inc;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, considering the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 13, 2019	By:	/s/ Clark A. Marcus
		Clark A. Marcus, Chief Executive Officer

EX-31.2

EXHIBIT 31.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Arnold B. Finestone, certify that:

6. I have reviewed this Quarterly Report on Form 10-Q of Advanzeon Solutions, Inc;

7. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, considering the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

8. Based on my knowledge, the financial statements, and other financial information included in this report, present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

9. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

10. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 13, 2019	By:	/s/ Arnold B. Finestone
		Arnold B. Finestone, President and Chief Financial Officer

EX-32.1

EXHIBIT 32.1

SECTION 906 CERTIFICATION

CERTIFICATION REQUIRED BY

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE

SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Advanzeon Solutions, Inc. (the "Company") on Form 10-Q for the quarterly period ended June 30, 2019, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 13, 2019	By:	/s/ Clark A. Marcus
		Clark A. Marcus, Chief Executive Officer

EX-32.2

EXHIBIT 32.2

SECTION 906 CERTIFICATION

CERTIFICATION REQUIRED BY

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE

SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Advanzeon Solutions, Inc. (the "Company") on Form 10-Q for the quarterly period ended June 30, 2019, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 13, 2019	By:	/s/ Arnold B. Finestone
		Arnold B. Finestone, President and Chief Financial Officer

XML

Related Party Loans Payable (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Related Party Transactions [Abstract]
Related party loans payable	$ 444,920	$ 737,023

XML

Property and Equipment (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
PROPERTY, PLANT, AND EQUIPMENT
Property and equipment	$ 1,549
Less accumulated depreciation	(225)
Property and equipment - net	$ 1,324

XML

Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2019	Dec. 31, 2018
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, authorized	1,000,000	1,000,000
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized	1,000,000,000	1,000,000,000
Common stock, issued	67,361,656	66,661,656
Common stock, outstanding	67,361,656	66,661,656
Series C Convertible Preferred [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, authorized	14,400	14,400
Preferred stock, issued	10,434	10,434
Preferred stock, outstanding	10,434	10,434
Series D Convertible Preferred [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, authorized	7,000	7,000
Preferred stock, issued	250	250
Preferred stock, outstanding	250	250
Remaining Preferred stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, authorized	978,600	978,600

XML

Description of The Company's Business and Basis of Presentation

9 Months Ended

Sep. 30, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

DESCRIPTION OF THE COMPANY'S BUSINESS AND BASIS OF PRESENTATION

1. DESCRIPTION OF THE COMPANY’S BUSINESS AND BASIS OF PRESENTATION

The consolidated financial statements include the accounts of Advanzeon Solutions, Inc and its wholly owned subsidiary, and its respective subsidiaries (collectively referred to herein as, the “Company,” “Advanzeon,” “we”, “us,” or “our”).

In the opinion of management, the accompanying unaudited financial statements contain all adjustments necessary to present fairly the Company's financial position as of December 31, 2018, the changes therein for the three and nine month periods then ended and the results of operations for the three and nine month periods ended September 30, 2019 and 2018.

The financial statements included in the Form 10-Q are presented in accordance with the requirements of the Form and do not include all of the disclosures required by accounting principles general accepted in the United States of America. For additional information, reference is made to the Company's annual report on Form 10-K for the fiscal year ended December 31, 2018, filed May 24, 2019. The results of operations for the three and nine month periods ended September 30, 2019 and 2018, are not necessarily indicative of operating results for the full year.

XML

Right of Use Lease Liabilities (Tables)

9 Months Ended

Sep. 30, 2019

Notes to Financial Statements

Schedule of lease liabilities associated with future payments due under the leases

As of September 30, 2019, the lease liabilities associated with future payments due under the leases are as follows:

Total present value of future lease payments	$	390,260
Principal payments made as of the quarter
ended September 30, 2019		(94,064	)
Total right of use lease liabilities as of September 30, 2019	$	296,196

Schedule of future minimum lease payments under the right of use lease agreements

The following is a schedule of future minimum lease payments under the right of use lease agreements together with the present value of the net minimum lease payments as of September 30, 2019:

Total future minimum lease payments	$	317,251
Less present value discount		21,055
Total right of use lease liabilities as of September 30, 2019		296,196
Less current portion due within one year		124,311
Long-term right of use liabilities	$	171,885

Schedule of maturities of lease liabilities

Total maturities of lease liabilities as of September 30, 2019 are as follows:

	Total future
	minimum lease		Present value		Right of use
	payments		discount		lease liabilities
2020	$	136,858	$	12,547	$	124,311
2021	$	106,330	$	6,839	$	99,491
2022		74,063		1,669		72,394
	$	317,251	$	21,055	$	296,196

XML

Related Party Loans Payable

9 Months Ended

Sep. 30, 2019

Related Party Transactions [Abstract]

RELATED PARTY LOANS PAYABLE

6. RELATED PARTY LOANS PAYABLE

The Company has received financing from Management of the Company as well as from members of our Board of Directors. These individuals are deemed to be related parties to the Company and their indebtedness must be disclosed separately.

As of September 30, 2019 and December 31, 2018, there are the following related party notes payable:

	September 30, 2019		December 31, 2018
Related party loans payable	$	444,920	$	737,023

XML

Right of Use Assets

9 Months Ended

Sep. 30, 2019

Notes to Financial Statements

RIGHT OF USE ASSETS

10. RIGHT OF USE ASSETS

The Company entered into two leases for office space and one automobile lease prior to the end of the quarter ended September 30, 2019 that are classified as right of use assets and lease liabilities. The lease for the Company’s office spaces expire in April 2020 and June 2022. The lease for the automobile expires in June 2021. As the implicit interest rate is not readily identifiable in the leases, the Company calculated the present a value of the leases using the average commercial real estate interest rate of 5.50% at the commencement of the office leases and the interest of 2.99% for the automobile lease. Applying the commercial rate, the Company calculated the present value of $361,223 for the office leases and $29,037 for the automobile leasing, that are being amortized over the life of the leases.

As of September 30, 2019, the right of use assets associated with future operating leases are as follows:

Total present value of right of use assets
under lease agreements	$	390,260
Amortization of right of use assets		(94,064	)
Total right of use assets as of September 30, 2019	$	296,196

Total amortization expense related to the right of use assets under the lease agreements was $62,135 and $0 for the nine month periods ended September 30, 2019 and 2018, respectively.

XML

Right of Use Lease Liabilities (Details 1) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Right Of Use Lease Liabilities
Total future minimum lease payments	$ 317,251
Less present value discount	21,055
Total right of use lease liabilities as of September 30, 2019	296,196
Less current portion due within one year	124,311	$ 53,634
Long-term right of use liabilities	$ 171,885	$ 28,920

XML

Right of Use Lease Liabilities (Details)	Sep. 30, 2019 USD ($)
Right Of Use Lease Liabilities
Total present value of future lease payments	$ 390,260
Principal payments made as of the quarter ended September 30, 2019	(94,064)
Total right of use lease liabilities as of September 30, 2019	$ 296,196

XML

Contingent Liability (Details Narrative) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Disputed interest payable	$ 171,247	$ 171,247
Attorney fees	21,412	$ 21,412
Son of Former Note Holder [Member]
Contingent liability	450,000
Disputed interest payable	171,247
Attorney fees	$ 21,412

XML

Debt (Details 1) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Notes payable	$ 12,163,189	$ 10,087,939
Advanzeon Parent [Member]
Notes payable	5,010,016	5,010,016
Pharmacy Value Management Solutions Inc.[Member]
Notes payable	$ 7,153,173	$ 5,077,923

XML

Subsequent Events

9 Months Ended

Sep. 30, 2019

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

14. SUBSEQUENT EVENTS

In accordance with ASC Topic 855, “Subsequent Events”, the Company evaluated subsequent events through November 13, 2019, the date these financial statements were available to be issued. During its evaluation, the following subsequent events were identified:

Issuance of debt and warrants

Subsequent to the balance sheet date, the Company has issued $139,000 of convertible-promissory notes. All of the debt matures in 2020 and has a stated interest rate of 12% and is unsecured. Concurrent with the issuance of debt, the Company has issued 4,128,000 warrants at an average exercise price of $0.15 At the time of issuance, all warrants had a three or five year term.

Stock issued for services

 The Company issued 4,300,000 shares of restricted common stock to the investment banker, D. H. Blair Investment Banking Corp. The services were valued at $473,000 or $0.11 per share.

XML

Property and Equipment (Tables)

9 Months Ended

Sep. 30, 2019

PROPERTY, PLANT, AND EQUIPMENT

Schedule of property and equipment, net

Property and equipment, net, consists of the following at September 30, 2019 and December 31, 2018:

	September 30, 2019			December 31, 2018
Property and equipment	$	1,549		$	—
Less accumulated depreciation		(225	)		—
Property and equipment - net	$	1,324		$	—

XML

Contingent Liability (Tables)

9 Months Ended

Sep. 30, 2019

Contingent Liability

Schedule of contingent liability

As of September 30, 2019 and December 31, 2018, the balance of this indebtedness is as follows:

	September 30, 2019		December 31, 2018
Disputed note payable	$	450,000	$	450,000
Disputed interest payable		171,247		171,247
Pending attorney fees		21,412		21,412
Total contingent liability	$	642,659	$	642,659

XML

Contingent Liability (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Contingent Liability
Disputed note payable	$ 450,000	$ 450,000
Disputed interest payable	171,247	171,247
Pending attorney fees	21,412	21,412
Total contingent liability	$ 642,659	$ 642,659

XML

Debt (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Notes Payable [Abstract]
Notes payable	$ 12,163,189	$ 10,087,939

XML

Right of Use Assets (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Lease, description	The Company entered into two leases for office space and one automobile lease prior to the end of the quarter ended September 30, 2019 that are classified as right of use assets and lease liabilities. The lease for the Company’s office spaces expire in April 2020 and June 2022. The lease for the automobile expires in June 2021. As the implicit interest rate is not readily identifiable in the leases, the Company calculated the present a value of the leases using the average commercial real estate interest rate of 5.50% at the commencement of the office leases and the interest of 2.99% for the automobile lease. Applying the commercial rate, the Company calculated the present value of $361,223 for the office leases and $29,037 for the automobile leasing, that are being amortized over the life of the leases.
Total amortization expenses	$ 62,135	$ 0
Automobiles [Member]
Present value of lease	$ 29,037
Interest rate	2.99%
Office [Member]
Present value of lease	$ 361,223
Interest rate	5.50%

XML

Other Accrued Liabilities (Tables)

9 Months Ended

Sep. 30, 2019

Other Accrued Liabilities

Schedule of other accrued liabilities

As of September 30, 2019 and December 31, 2018, the balance of other accrued liabilities is as follows:

	September 30, 2019		December 31, 2018
Management compensation	$	8,873,802	$	8,873,802
Accrued interest non-related party		5,839,509		4,809,644
Board of Director fees		1,012,500		900,000
State fees		—		21,000
Payroll liabilities		3,725		2,927
Accrued wages and related		4,609		7,399
Total other accrued debt	$	15,734,145	$	14,614,772

XML

Summary of Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2019

Accounting Policies [Abstract]

Use of Estimates

Use of Estimates - The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts. Actual results could differ from these estimates. Estimates involved in the determination of an allowance for doubtful accounts receivable are considered by management as particularly susceptible to material change in the next year. Other significant estimates relate to stock-based compensation, warrants and beneficial conversion features. 

Accounts Receivable

Accounts Receivable - Accounts receivable is carried at its estimated collectible value. Since customer credit is generally extended on a short-term basis, accounts receivable does not bear interest and are uncollateralized. We manage credit risk and determine necessary allowances by evaluating customers’ credit worthiness before extending credit and periodically for collectability, based primarily on customers’ past credit history and current financial conditions and general economic conditions, results of prior collection efforts, the relative strength of our relationship therewith and, in the event of a dispute, its legal position and the estimated cost of proposed collection proceedings. Management has not established a policy for when to charge off uncollectible accounts receivable or to use external collection agencies and makes such decisions on a case-by-case basis. The maximum losses that the Company would incur if a customer failed to pay would be limited to the carrying value of the receivable.

Revenue recognition

Revenue Recognition- The Company is on an accrual basis and revenue is recognized when billed, which is approximately when the testing service is performed or CPAP machine is shipped.

Property and Equipment

Property and Equipment - Property and equipment, as described in Note 4, is stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives ranging from 2 to 12 years.

Leasehold Improvement

Leasehold Improvement - Leasehold improvement, as described in Note 5, is stated at cost less accumulated amortization. Leasehold improvements are amortized over the shorter of the lease term or the asset’s useful life.

Fair Value Measurements

Fair Value Measurements - The carrying amounts of cash, accounts receivable and accounts payable approximate their estimated fair value due to the short-term nature of these instruments. Since our other financial liabilities are not traded in an open market, we generally use a present value technique, which is a level 3 input, as defined in GAAP, to measure the estimated fair value of these financial instruments, except for valuing stock options and warrants (see below). The rate used for discounting expected cash flows is a risk-free rate adjusted for systematic and unsystematic risk.

The carrying amounts of long-term debt and estimated fair values of the attached warrants at September 30, 2019 and December 31, 2018 are as follows:

	September 30, 2019				December 31, 2018
			Estimated				Estimated
			Fair Value of				Fair Value of
	Carrying		Attached		Carrying		Attached
	Amount		Warrants		Amount		Warrants
Convertible promissory notes	$	7,375,173	$	—	$	5,299,923	$	—
Short term notes payable	$	4,788,016	$	—	$	4,788,016	$	—
Loan payable related party		444,920		—		737,023		—
	$	12,608,109	$	—	$	10,824,962	$	—

During the nine month period ended September 30, 2019, there have been 47 additional convertible notes issued totaling $2,100,250 and one note paid off totaling $25,000.

Cost of Revenues

Cost of Revenues- Costs of services consist of supplies and operating expenses. Supplies are recognized in the period in which a patient actually receives the supplies.

Right of Use Assets and Lease Liabilities

Right of Use Assets and Lease Liabilities - During the quarter ended March 31, 2019, the Company implemented Accounting Standards Update 2016-02, Leases. Under the new guidance, a lessee must record a liability for lease payments (referred to as the lease liability) and an asset for the right to use the leased asset during the lease term (referred to at the right of use asset) for all leases, regardless of whether they are designated as finance or operating leases. This election requires the lessee to recognize lease expense on a straight-line basis over the lease term. The right of use assets and corresponding right of use liabilities have been recorded using the present value of the leases. See Notes 10 and 11 within the financial statement for additional disclosure on leases.

Income Taxes

Income Taxes - We are subject to the income tax jurisdictions of the U.S. and multiple state tax jurisdictions. However, our provisions for income taxes for 2018 and 2019 include only state income taxes.

Management has evaluated our tax positions taken or to be taken on income tax returns that remain subject to examination (i.e., tax years 2016 and thereafter federally), and has concluded that there have been no uncertain tax positions (as defined in GAAP) taken that require recognition or disclosure in the consolidated financial statements. In the event of any income tax-related interest or penalties are incurred, they would be included in general and administrative expense.

Stock Options and Warrants

Stock Options and Warrants - We grant stock options and warrants to our employees, non-employee directors, note holders and certain consultants allowing them to purchase our common stock pursuant to approved terms. The estimated value of the warrants issued with debt instruments is recorded as a discount on notes payable and amortized as interest expense over the term of the notes using the effective interest method.

XML

Leasehold Improvement (Tables)

9 Months Ended

Sep. 30, 2019

Leases [Abstract]

Schedule of leasehold improvement, net

Leasehold improvement, net, consists of the following at September 30, 2019 and December 31, 2018:

	September 30, 2019			December 31, 2018
Leasehold improvements	$	2,992		$	2,992
Less accumulated amortization		(2,992	)		(2,693	)
Leasehold improvements - net	$	—		$	299

XML

Other Current Assets (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Other Current Assets
Due from escrow account	$ 1,918,898	$ 472,788
Loans to others	22,459
Security deposit	5,500	13,500
Capitalized portion of lease	2,094	2,951
Prepaid expenses	71,394	5,248
Miscellaneous receivable	334,509	334,509
Other current asset	$ 2,354,854	$ 828,996

XML

Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
CURRENT ASSETS
Cash	$ 64,057	$ 25,036
Accounts receivable	25,171	24,890
Current portion of right of use asset	124,311	53,634
Other current assets	2,354,854	828,996
Total current assets	2,568,393	932,556
PROPERTY, PLANT, AND EQUIPMENT
Property and equipment, net	1,324
Leasehold improvements, net		299
Total property, plant, and equipment	1,324	299
RIGHT OF USE ASSET, NET OF CURRENT PORTION	171,885	28,920
TOTAL ASSETS	2,741,602	961,775
CURRENT LIABILITIES
Related party loans payable	444,920	737,023
Account payable	1,423,284	700,067
Debt	12,163,189	10,087,939
Contingent liability	642,659	642,659
Current portion of lease liability	124,311	53,634
Other accrued expenses	15,734,145	14,614,772
Total current liabilities	30,532,508	26,836,094
LEASE LIABILITY, NET OF CURRENT PORTION	171,885	28,920
TOTAL LIABILITIES	30,704,393	26,865,014
STOCKHOLDERS' DEFICIENCY
Preferred stock, value
Common stock, $0.01 par value; 1,000,000,000 shares authorized; 67,361,656 and 66,661,656 shares issued and outstanding as of Septmeber 30, 2019 and December 31, 2018	673,617	666,617
Additional paid in capital	28,036,007	28,012,007
Accumulated deficit	(56,672,425)	(54,581,873)
Total stockholders' deficiency	(27,962,791)	(25,903,239)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIENCY	2,741,602	961,775
Series C Convertible Preferred [Member]
STOCKHOLDERS' DEFICIENCY
Preferred stock, value	10	10
Series D Convertible Preferred [Member]
STOCKHOLDERS' DEFICIENCY
Preferred stock, value
Remaining Preferred stock [Member]
STOCKHOLDERS' DEFICIENCY
Preferred stock, value

XML

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
CASH FLOWS FROM OPERATING ACTIVITIES
Net (loss) income	$ (2,090,552)	$ 5,485,345
Adjustments to reconcile net (loss) income to net cash used in operating activities:
Depreciation and amortization	524	449
Stock issued for services	16,000	240,000
Extinguishment of loan due to shareholder and accrued interest		(7,771,140)
Amortization of right of use assets	62,135
Net changes in assets and liabilities:
Accounts receivable	(281)	(34,493)
Other current assets	(1,525,858)	(700,842)
Payments on lease liabilities	(62,135)
Accounts payable	431,114	520,379
Contingent liability		152,664
Accrued interest - related party		(246,568)
Other accrued expenses	1,119,373	1,328,842
Net cash used in operating activities	(2,049,680)	(1,025,364)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property, plant, and equipment	(1,549)
Net cash used in investing activities	(1,549)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from promissory notes	2,100,250	1,079,223
Payments on debt	(25,000)
Sale of stock	15,000
Net cash provided by financing activities	2,090,250	1,079,223
Net increase in cash	39,021	53,859
CASH - Beginning of Year	25,036	18,200
CASH - END OF PERIOD	64,057	72,059
Supplemental disclosures of cash flow information:
Cash paid during the period for: Interest	6,960
Cash paid during the period for: Income taxes
Recording of right of use assets under lease agreements (ASU 2016-02)	390,260
Schedule of non-cash investing transactions:
Convertible promissory note converted to common stock		$ 51,231

XML

Right of Use Assets (Tables)

9 Months Ended

Sep. 30, 2019

Notes to Financial Statements

Schedule of right of use assets associated with future operating leases

As of September 30, 2019, the right of use assets associated with future operating leases are as follows:

Total present value of right of use assets
under lease agreements	$	390,260
Amortization of right of use assets		(94,064	)
Total right of use assets as of September 30, 2019	$	296,196

XML

Leasehold Improvement (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Leases [Abstract]
Amortization expense	$ 299	$ 449

XML

Debt

9 Months Ended

Sep. 30, 2019

Notes Payable [Abstract]

Debt

7. DEBT

As of September 30, 2019 and December 31, 2018, the balance was as follows:

	September 30, 2019		December 31, 2018
Notes payable	$	12,163,189	$	10,087,939

During the nine month period ended September 30, 2019, there have been 47 additional convertible-promissory notes totaling $2,100,250. One $25,000 convertible promissory note was repaid with interest of $6,960 during the third quarter 2019. One previous $50,000 convertible-promissory note was converted into stock during the year ended December 31, 2018.

Break-out of debt between the parent company and our subsidiary PVMS is as follows:

	September 30, 2019		December 31, 2018
Advanzeon parent	$	5,010,016	$	5,010,016
PVMS		7,153,173		5,077,923
	$	12,163,189	$	10,087,939

At PVMS, the total of notes issued year-to-date and their dollar values were as follows:

	September 30, 2019		December 31, 2018
Number of notes issued		47		31
Dollar value	$	2,100,250	$	1,751,923

All debt are short-term in nature, one-year maturity date. All debt issued has a stated interest rate of 12% per year.

XML

Right of Use Lease Liabilities

9 Months Ended

Sep. 30, 2019

Notes to Financial Statements

RIGHT OF USE LEASE LIABILITIES

11. RIGHT OF USE LEASE LIABILITIES

As disclosed in Note 10, the Company entered into two leases for office space and automobile lease prior to the quarter ended September 30, 2019 that are classified as right of use assets and lease liabilities.

As of September 30, 2019, the lease liabilities associated with future payments due under the leases are as follows:

Total present value of future lease payments	$	390,260
Principal payments made as of the quarter
ended September 30, 2019		(94,064	)
Total right of use lease liabilities as of September 30, 2019	$	296,196

The following is a schedule of future minimum lease payments under the right of use lease agreements together with the present value of the net minimum lease payments as of September 30, 2019:

Total future minimum lease payments	$	317,251
Less present value discount		21,055
Total right of use lease liabilities as of September 30, 2019		296,196
Less current portion due within one year		124,311
Long-term right of use liabilities	$	171,885

Total maturities of lease liabilities as of September 30, 2019 are as follows:

	Total future
	minimum lease		Present value		Right of use
	payments		discount		lease liabilities
2020	$	136,858	$	12,547	$	124,311
2021	$	106,330	$	6,839	$	99,491
2022		74,063		1,669		72,394
	$	317,251	$	21,055	$	296,196

XML

Right of Use Lease Liabilities (Details 2)	Sep. 30, 2019 USD ($)
Total future minimum lease payments	$ 317,251
Present value discount	21,055
Right of use lease liabilities	296,196
2020 [Member]
Total future minimum lease payments	136,858
Present value discount	12,547
Right of use lease liabilities	124,311
2021 [Member]
Total future minimum lease payments	106,330
Present value discount	6,839
Right of use lease liabilities	99,491
2022 [Member]
Total future minimum lease payments	74,063
Present value discount	1,669
Right of use lease liabilities	$ 72,394

XML

Other Accrued Liabilities (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Other Accrued Liabilities
Management compensation	$ 8,873,802	$ 8,873,802
Accrued interest non-related party	5,839,509	4,809,644
Board of Director fees	1,012,500	900,000
State fees	0	21,000
Payroll liabilities	3,725	2,927
Accrued wages and related	4,609	7,399
Total other accrued debt	$ 15,734,145	$ 14,614,772

XML

Debt (Details 2) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Number of notes issued	25
Pharmacy Value Management Solutions Inc.[Member]
Number of notes issued	47	31
Dollar value	$ 2,100,250	$ 1,751,923

XML

Other Current Assets (Tables)

9 Months Ended

Sep. 30, 2019

Other Current Assets

Schedule of other current assets

Other current assets consists of the following at September 30, 2019 and December 31, 2018:

	September 30, 2019		December 31, 2018
Due from escrow account	$	1,918,898	$	472,788
Loans to others		22,459		—
Security deposit		5,500		13,500
Capitalized portion of lease		2,094		2,951
Prepaid expenses		71,394		5,248
Miscellaneous receivable		334,509		334,509
Other current asset	$	2,354,854	$	828,996

XML

Debt (Tables)

9 Months Ended

Sep. 30, 2019

Notes Payable [Abstract]

Schedule of notes payable

As of September 30, 2019 and December 31, 2018, the balance was as follows:

	September 30, 2019		December 31, 2018
Notes payable	$	12,163,189	$	10,087,939

Schedule of break-out of debt

Break-out of debt between the parent company and our subsidiary PVMS is as follows:

	September 30, 2019		December 31, 2018
Advanzeon parent	$	5,010,016	$	5,010,016
PVMS		7,153,173		5,077,923
	$	12,163,189	$	10,087,939

Schedule of notes issued

At PVMS, the total of notes issued year-to-date and their dollar values were as follows:

	September 30, 2019		December 31, 2018
Number of notes issued		47		31
Dollar value	$	2,100,250	$	1,751,923

XML

Leasehold Improvement

9 Months Ended

Sep. 30, 2019

Leases [Abstract]

LEASEHOLD IMPROVEMENT

5. LEASEHOLD IMPROVEMENT

Leasehold improvement, net, consists of the following at September 30, 2019 and December 31, 2018:

	September 30, 2019			December 31, 2018
Leasehold improvements	$	2,992		$	2,992
Less accumulated amortization		(2,992	)		(2,693	)
Leasehold improvements - net	$	—		$	299

Amortization expense for the nine month periods ended September 30, 2019 and 2018 is $299 and $449, respectively.

XML

Other Accrued Liabilities

9 Months Ended

Sep. 30, 2019

Other Accrued Liabilities

OTHER ACCRUED LIABILITIES

9. OTHER ACCRUED LIABILITIES

As of September 30, 2019 and December 31, 2018, the balance of other accrued liabilities is as follows:

	September 30, 2019		December 31, 2018
Management compensation	$	8,873,802	$	8,873,802
Accrued interest non-related party		5,839,509		4,809,644
Board of Director fees		1,012,500		900,000
State fees		—		21,000
Payroll liabilities		3,725		2,927
Accrued wages and related		4,609		7,399
Total other accrued debt	$	15,734,145	$	14,614,772

XML

Legal Proceedings

9 Months Ended

Sep. 30, 2019

Legal Proceedings

LEGAL PROCEEDINGS

13. LEGAL PROCEEDINGS

The Company previously reported that the litigation between Rotech Healthcare, Inc. and Pharmacy Value Management Solutions, Inc. settled. The Company rejected the draft settlement terms and continues to aggressively defend this litigation.

Except as disclosed above and in Item 1, all of the legal proceedings for the nine-month period ended September 30, 2019, are disclosed in our annual report on Form10-K for the year ended December 31, 2018, filed on May 24, 2019.

XML

Property and Equipment (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
PROPERTY, PLANT, AND EQUIPMENT
Depreciation expense	$ 225	$ 0

XML

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Revenues:
Obstructive sleep apnea (OSA)	$ 68,173	$ 99,083	$ 226,549	$ 449,650
Total revenues	68,173	99,083	226,549	449,650
Costs and expenses:
Costs of revenues	2,394	46,028	110,211	280,372
General and administrative	428,077	409,419	1,269,920	1,396,478
Depreciation and amortization	84	149	524	449
Total costs and expenses	430,555	455,596	1,380,655	1,677,299
Loss from operations	(362,382)	(356,513)	(1,154,106)	(1,227,649)
Other income (expense):
Interest expense	(383,798)	(307,922)	(1,052,991)	(1,148,795)
Interest income	29		6,023
Legal settlement			112,172	328,269
State tax penalty	(1,650)		(1,650)
Extinguishment of loan due to shareholder				7,771,140
Settlement of prior accounting services				(240,000)
Other income				2,380
Total other income (expense)	(385,419)	(307,922)	(936,446)	6,712,994
Income taxes
Net (loss) income	$ (747,801)	$ (664,435)	$ (2,090,552)	$ 5,485,345
PER SHARE INFORMATION
Net (Loss) Income Per Common Share	$ (0.01)	$ (0.01)	$ (0.03)	$ 0.08
Weighted Average Number of Common Shares Outstanding	67,361,656	66,661,656	67,140,411	65,849,175

XML

Summary of Significant Accounting Policies (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Schedule of carrying and estimated fair values of financial instruments
Carrying Amount	$ 12,608,109	$ 10,824,962
Estimated Fair Value of Attached Warrants
Convertible Promissory Notes [Member]
Schedule of carrying and estimated fair values of financial instruments
Carrying Amount	7,375,173	5,299,923
Estimated Fair Value of Attached Warrants
Short Term Notes Payable [Member]
Schedule of carrying and estimated fair values of financial instruments
Carrying Amount	4,788,016	4,788,016
Estimated Fair Value of Attached Warrants
Loans Payable Related Party [Member]
Schedule of carrying and estimated fair values of financial instruments
Carrying Amount	444,920	737,023
Estimated Fair Value of Attached Warrants

XML

Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2019

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Established in 1969, Advanzeon Solutions, Inc., (formerly Comprehensive Care Corp.) (“Advanzeon”, “we”, “Parent”, or the “Company”), through its wholly-owned subsidiary Pharmacy Value Management Solutions, Inc.,(“PVMS”) and its wholly-owned subsidiaries during 2015, and partly in 2016, provided managed care services by acting as the administrator for certain administrative service agreements in the behavioral health and substance abuse fields. We primarily offered these services to commercial, Medicare, Medicaid, Children’s Health Insurance Program (“CHIP”) health plans, as well as self-insured companies. Our managed care operations consisted solely of servicing administrative service agreements. Starting in July of 2015, we implemented our comprehensive sleep apnea program, called “SleepMaster Solutions” ™. SleepMaster Solutions (“SMS”) utilizes an administrative system for the convenient identification/testing and therapy of Obstructive Sleep Apnea (“OSA”). We partnered with a national health care provider by initiating a sleep apnea wellness program whereby we screened, tested and when needed, offered treatment programs for treating this disorder. We also contracted with a union to treat its driver members. Beginning in 2017, our only business was our SMS sleep apnea program.

The Company has elected to not adopt the option available under United States generally accepted accounting principles (“GAAP”) to measure any eligible financial instruments or other items at fair market value at this time. Accordingly, the Company measures all of its assets and liabilities on the historical cost basis of accounting, except as otherwise required by GAAP.

Inter-company accounts and transactions have been eliminated in consolidation. Certain minor reclassifications of prior period amounts have been made to conform to the current period presentation.

Use of Estimates - The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts. Actual results could differ from these estimates. Estimates involved in the determination of an allowance for doubtful accounts receivable are considered by management as particularly susceptible to material change in the next year. Other significant estimates relate to stock-based compensation, warrants and beneficial conversion features. 

Accounts Receivable - Accounts receivable is carried at its estimated collectible value. Since customer credit is generally extended on a short-term basis, accounts receivable does not bear interest and are uncollateralized. We manage credit risk and determine necessary allowances by evaluating customers’ credit worthiness before extending credit and periodically for collectability, based primarily on customers’ past credit history and current financial conditions and general economic conditions, results of prior collection efforts, the relative strength of our relationship therewith and, in the event of a dispute, its legal position and the estimated cost of proposed collection proceedings. Management has not established a policy for when to charge off uncollectible accounts receivable or to use external collection agencies and makes such decisions on a case-by-case basis. The maximum losses that the Company would incur if a customer failed to pay would be limited to the carrying value of the receivable.

Revenue Recognition- The Company is on an accrual basis and revenue is recognized when billed, which is approximately when the testing service is performed or CPAP machine is shipped.

Property and Equipment - Property and equipment, as described in Note 4, is stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives ranging from 2 to 12 years.

Leasehold Improvement - Leasehold improvement, as described in Note 5, is stated at cost less accumulated amortization. Leasehold improvements are amortized over the shorter of the lease term or the asset’s useful life.

Fair Value Measurements - The carrying amounts of cash, accounts receivable and accounts payable approximate their estimated fair value due to the short-term nature of these instruments. Since our other financial liabilities are not traded in an open market, we generally use a present value technique, which is a level 3 input, as defined in GAAP, to measure the estimated fair value of these financial instruments, except for valuing stock options and warrants (see below). The rate used for discounting expected cash flows is a risk-free rate adjusted for systematic and unsystematic risk.

The carrying amounts of long-term debt and estimated fair values of the attached warrants at September 30, 2019 and December 31, 2018 are as follows:

	September 30, 2019				December 31, 2018
			Estimated				Estimated
			Fair Value of				Fair Value of
	Carrying		Attached		Carrying		Attached
	Amount		Warrants		Amount		Warrants
Convertible promissory notes	$	7,375,173	$	—	$	5,299,923	$	—
Short term notes payable	$	4,788,016	$	—	$	4,788,016	$	—
Loan payable related party		444,920		—		737,023		—
	$	12,608,109	$	—	$	10,824,962	$	—

During the nine month period ended September 30, 2019, there have been 47 additional convertible notes issued totaling $2,100,250 and one note paid off totaling $25,000.

Cost of Revenues- Costs of services consist of supplies and operating expenses. Supplies are recognized in the period in which a patient actually receives the supplies.

Right of Use Assets and Lease Liabilities - During the quarter ended March 31, 2019, the Company implemented Accounting Standards Update 2016-02, Leases. Under the new guidance, a lessee must record a liability for lease payments (referred to as the lease liability) and an asset for the right to use the leased asset during the lease term (referred to at the right of use asset) for all leases, regardless of whether they are designated as finance or operating leases. This election requires the lessee to recognize lease expense on a straight-line basis over the lease term. The right of use assets and corresponding right of use liabilities have been recorded using the present value of the leases. See Notes 10 and 11 within the financial statement for additional disclosure on leases.

Income Taxes - We are subject to the income tax jurisdictions of the U.S. and multiple state tax jurisdictions. However, our provisions for income taxes for 2018 and 2019 include only state income taxes.

Management has evaluated our tax positions taken or to be taken on income tax returns that remain subject to examination (i.e., tax years 2016 and thereafter federally), and has concluded that there have been no uncertain tax positions (as defined in GAAP) taken that require recognition or disclosure in the consolidated financial statements. In the event of any income tax-related interest or penalties are incurred, they would be included in general and administrative expense.

Stock Options and Warrants - We grant stock options and warrants to our employees, non-employee directors, note holders and certain consultants allowing them to purchase our common stock pursuant to approved terms. The estimated value of the warrants issued with debt instruments is recorded as a discount on notes payable and amortized as interest expense over the term of the notes using the effective interest method.

XML

Subsequent Events (Details Narrative) - USD ($)	1 Months Ended	9 Months Ended
	Nov. 13, 2019	Sep. 30, 2019	Sep. 30, 2018
Stock issued for services		$ 16,000	$ 240,000
Stock issued for services, shares			2,000,000
Share Price		$ 0.08	$ 0.12
Subsequent Event [Member] | Investment Banker
Stock issued for services	$ 473,000
Stock issued for services, shares	4,300,000
Share Price	$ .11
Subsequent Event [Member] | Warrant [Member]
Number of warrant issued	4,128,000
Exercise price of warrants (in dollars per share)	$ 0.15
Subsequent Event [Member] | Warrant [Member] | Minimum [Member]
Warrant term	3 years
Subsequent Event [Member] | Warrant [Member] | Maximum [Member]
Warrant term	5 years
Subsequent Event [Member] | Convertible-promissory notes [Member]
Face amount	$ 139,000
Maturity date	All of the debt matures in 2020
Interest rate	12.00%

XML

Common Stock

9 Months Ended

Sep. 30, 2019

Common Stock Abstract

COMMON STOCK

12. COMMON STOCK

During the nine month period ended September 30, 2019, the Company issued 700,000 shares of its common stock as follows:

On March 21, 2019, the Company issued 200,000 shares of its common stock to its Securities Exchange Commission counsel, who elected to take common stock in the Company as partial payment of its legal fees. The total value shares were valued at $0.08 per share on the total value of $16,000.

Additionally, on March 29, 2019, the Company issued 500,000 shares of its common stock to an existing shareholder and warrant holder, who elected to exercise his warrants to purchase 500,000 shares of the Company's common stock for $15,000. The warrants were issued during May of 2017 for $0.03 per share.

During the nine month period ended September 30, 2018, the Company issued 2,000,000 shares of common stock for a legal settlement. The shares were issued at a value of $0.12 per share or for a total value of $240,000. In addition, the Company issued 1,597,971 shares for the conversion of a promissory note of $50,000 and accrued interest of $1,231. The stock was issued at a value of $0.03 per share. The Company relied on Section 4(a)(2) of the Securities Act of 1933, as amended, as the exemption from registration under the Act.

XML

Property and Equipment

9 Months Ended

Sep. 30, 2019

PROPERTY, PLANT, AND EQUIPMENT

PROPERTY AND EQUIPMENT

4. PROPERTY AND EQUIPMENT

Property and equipment, net, consists of the following at September 30, 2019 and December 31, 2018:

	September 30, 2019			December 31, 2018
Property and equipment	$	1,549		$	—
Less accumulated depreciation		(225	)		—
Property and equipment - net	$	1,324		$	—

Depreciation expense for the nine month periods ended September 30, 2019 and 2018 is $225 and $0, respectively. A computer was acquired in February of 2019.

XML

Contingent Liability

9 Months Ended

Sep. 30, 2019

Contingent Liability

CONTINGENT LIABILITY

8. CONTINGENT LIABILITY

Contingent liability consisted of 3 items:

1. a lawsuit against the Company for $450,000 from the son of a deceased promissory note holder. This matter has been dismissed twice by the judge but is ongoing due to appeals. This case should expire in June or July for lack of prosecution.

2. interest payable in the amount of $171,247 to the same person listed in (1). This interest is related to the lawsuit reference in (1).

3. Advanzeon won a decision on a court case against Universal Healthcare. The attorney's fees relating to this matter total $21,412. This fee will be paid out of the proceeds of the case when collected.

As of September 30, 2019 and December 31, 2018, the balance of this indebtedness is as follows:

	September 30, 2019		December 31, 2018
Disputed note payable	$	450,000	$	450,000
Disputed interest payable		171,247		171,247
Pending attorney fees		21,412		21,412
Total contingent liability	$	642,659	$	642,659

XML

Other Current Assets

9 Months Ended

Sep. 30, 2019

Other Current Assets

OTHER CURRENT ASSETS

3. OTHER CURRENT ASSETS

 
Other current assets consists of the following at September 30, 2019 and December 31, 2018:

	September 30, 2019		December 31, 2018
Due from escrow account	$	1,918,898	$	472,788
Loans to others		22,459		—
Security deposit		5,500		13,500
Capitalized portion of lease		2,094		2,951
Prepaid expenses		71,394		5,248
Miscellaneous receivable		334,509		334,509
Other current asset	$	2,354,854	$	828,996

XML

Leasehold Improvement (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Leasehold improvement		$ 299
Leasehold Improvements [Member]
Leasehold improvement	2,992	2,992
Less accumulated amortization	(2,992)	(2,693)
Leasehold improvement - net		$ 299

XML

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2019	Nov. 13, 2019
Document and Entity Information [Abstract]
Entity Registrant Name	Advanzeon Solutions, Inc.
Entity Central Index Key	0000022872
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	10-Q
Document Period End Date	Sep. 30, 2019
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2019
Entity Current Reporting Status	Yes
Entity File Number	1-9927
Entity Filer Category	Non-accelerated Filer
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Incorporation, State or Country Code	DE
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding		71,661,656

XML

Consolidated Statement of Stockholders' Deficiency Equity (Unaudited) - 9 months ended Sep. 30, 2019 - USD ($)	Series C Convertible Preferred Stock	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2018	$ 10	$ 666,617	$ 28,012,007	$ (54,581,873)	$ (25,903,239)
Balance, shares at Dec. 31, 2018	10,434	66,661,656
Stock issued for services		$ 2,000	14,000		16,000
Stock issued for services, shares		200,000
Sale of stock		$ 5,000	10,000		15,000
Sale of stock, shares		500,000
Net loss				(2,090,552)	(2,090,552)
Balance at Sep. 30, 2019	$ 10	$ 673,617	$ 28,036,007	$ (56,672,425)	$ (27,962,791)
Balance, shares at Sep. 30, 2019	10,434	67,361,656

XML

Summary of Significant Accounting Policies (Details Narrative)	9 Months Ended
	Sep. 30, 2019 USD ($) Number
Convertible notes	$ 2,100,250
Number of additional notes | Number	47
Repayment of note	$ 25,000
Property and equipment [Member] | Minimum [Member]
Useful Life	2 years
Property and equipment [Member] | Maximum [Member]
Useful Life	12 years

XML

Common Stock (Details Narrative) - USD ($)	1 Months Ended		9 Months Ended
	Mar. 29, 2019	Mar. 21, 2019	Sep. 30, 2019	Sep. 30, 2018	May 31, 2017
Number of shares issued			25
Share price			$ 0.08	$ 0.12
Stock issued for partial payment of legal fees, value			$ 16,000
Warrants to purchase shares			500,000
Value of common stock issued			$ 15,000
Warrants issued price					$ 0.03
Number of shares issued for legal settlement				2,000,000
Stock issued for settlement of accounting services, value			$ 16,000	$ 240,000
Number of shares issued in debt conversion (in shares)				1,597,971
Accrued interest				$ 1,231
Number of shares issued in debt conversion (in dollars per shares)				$ 50,000
Share price per share				$ 0.03
Common Stock [Member]
Number of shares issued	500,000	200,000	700,000
Number of shares issued for legal settlement			200,000
Stock issued for settlement of accounting services, value			$ 2,000

XML

Right of Use Assets (Details) - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Right Of Use Assets
Total present value of right of use assets under lease agreements	$ 390,260
Amortization of right of use assets	(94,064)
Total right of use assets as of September 30, 2019	$ 296,196

XML

Debt (Details Narrative)	3 Months Ended	9 Months Ended
	Sep. 30, 2019 USD ($) Number	Sep. 30, 2019 USD ($) Number	Dec. 31, 2018 USD ($)
Maturity date		One-year
Description of interest rate		All debt issued has a stated interest rate of 12% per year.
Number of additional notes | Number	47	47
Short Term One Note [Member]
Stated interest rate	12.00%	12.00%
Number of additional notes | Number	47	47
Debt converted into stock		$ 2,100,250
Convertible note payable			$ 50,000
Repayment of convertible promissory note	$ 25,000
Interest paid	$ 6,960

XML

Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2019

Accounting Policies [Abstract]

Schedule of carrying and estimated fair values of financial instruments

The carrying amounts of long-term debt and estimated fair values of the attached warrants at September 30, 2019 and December 31, 2018 are as follows:

	September 30, 2019				December 31, 2018
			Estimated				Estimated
			Fair Value of				Fair Value of
	Carrying		Attached		Carrying		Attached
	Amount		Warrants		Amount		Warrants
Convertible promissory notes	$	7,375,173	$	—	$	5,299,923	$	—
Short term notes payable	$	4,788,016	$	—	$	4,788,016	$	—
Loan payable related party		444,920		—		737,023		—
	$	12,608,109	$	—	$	10,824,962	$	—

XML

Related Party Loans Payable (Tables)

9 Months Ended

Sep. 30, 2019

Related Party Transactions [Abstract]

Schedule of related party notes payable

As of September 30, 2019 and December 31, 2018, there are the following related party notes payable:

	September 30, 2019		December 31, 2018
Related party loans payable	$	444,920	$	737,023